Renoprotective action of fenoldopam in high-risk patients undergoing cardiac surgery -: A prospective, double-blind, randomized clinical trial

被引:133
作者
Bove, T [1 ]
Landoni, G [1 ]
Calabrò, MG [1 ]
Aletti, G [1 ]
Marino, G [1 ]
Cerchierini, E [1 ]
Crescenzi, G [1 ]
Zangrillo, A [1 ]
机构
[1] Univ Milan, Dept Cardiovasc Anesthesia, IRCCS, Hosp San Raffaele, I-20132 Milan, Italy
关键词
cardiopulmonary bypass; diuretics; anesthesia; fenoldopam; kidney failure; acute;
D O I
10.1161/CIRCULATIONAHA.104.509141
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Background - Acute renal failure is a serious complication of cardiac surgery causing high morbidity and mortality. The aim of this study was to evaluate the usefulness of fenoldopam, a specific agonist of the dopamine- 1 receptor, in patients at high risk of perioperative renal dysfunction. Methods and Results - A prospective single- center, randomized, double- blind trial was performed after local ethical committee approval and after written consent was obtained from 80 patients undergoing cardiac surgery. Patients received either fenoldopam at 0.05 mu g/ kg per minute or dopamine at 2.5 mu g/ kg per minute after the induction of anesthesia for a 24- hour period. All these patients were at high risk of perioperative renal dysfunction as indicated by Continuous Improvement in Cardiac Surgery Program score > 10. Primary end point was defined as 25% creatinine increase from baseline levels after cardiac surgery. The 2 groups ( fenoldopam versus dopamine) were homogeneous cohorts, and no difference in outcome was observed. Acute renal failure was similar: 17 of 40 ( 42.5%) in the fenoldopam group and 16 of 40 ( 40%) in the dopamine group ( P = 0.9). Peak postoperative serum creatinine level, intensive care unit and hospital stay, and mortality were also similar in the 2 groups. Conclusions - Despite an increasing number of reports of renal protective properties from fenoldopam, we observed no difference in the clinical outcome compared with dopamine in a high- risk population undergoing cardiac surgery.
引用
收藏
页码:3230 / 3235
页数:6
相关论文
共 31 条
[1]
RENAL-FAILURE AFTER OPEN-HEART SURGERY [J].
BHAT, JG ;
GLUCK, MC ;
LOWENSTEIN, J ;
BALDWIN, DS .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (06) :677-682
[2]
Fenoldopam for renal protection in patients undergoing cardiopulmonary bypass [J].
Caimmi, PP ;
Pagani, L ;
Micalizzi, E ;
Fiume, C ;
Guani, S ;
Bernardi, M ;
Parodi, F ;
Cordero, G ;
Fregonara, M ;
Kapetanakis, E ;
Panella, M ;
De Gasperis, C .
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2003, 17 (04) :491-494
[3]
Independent association between acute renal failure and mortality following cardiac surgery [J].
Chertow, GM ;
Levy, EM ;
Hammermeister, KE ;
Grover, F ;
Daley, J .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (04) :343-348
[4]
Chertow GM, 1997, CIRCULATION, V95, P878
[5]
CORWIN HL, 1989, J THORAC CARDIOV SUR, V98, P1107
[6]
The agonising negative trend in monitoring of clinical trials [J].
DeMets, DL ;
Pocock, SJ ;
Julian, DG .
LANCET, 1999, 354 (9194) :1983-1988
[7]
The therapeutic potential of dopamine modulators on the cardiovascular and renal systems [J].
Doggrell, SA .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (05) :631-644
[8]
RENAL AND HEMODYNAMIC-EFFECTS OF INTRAVENOUS FENOLDOPAM VERSUS NITROPRUSSIDE IN SEVERE HYPERTENSION [J].
ELLIOTT, WJ ;
WEBER, RR ;
NELSON, KS ;
OLINER, CM ;
FUMO, MT ;
GRETLER, DD ;
MCCRAY, GR ;
MURPHY, MB .
CIRCULATION, 1990, 81 (03) :970-977
[9]
Predicting acute renal failure after coronary bypass surgery: Cross-validation of two risk-stratification algorithms [J].
Fortescue, EB ;
Bates, DW ;
Chertow, GM .
KIDNEY INTERNATIONAL, 2000, 57 (06) :2594-2602
[10]
GAILIUNAS P, 1980, J THORAC CARDIOV SUR, V79, P241